VIDEO: ASCO highlights ‘important’ presentations on targeted, immunotherapy in lung cancer

ByRavi Salgia, MD, PhD

ByMarley V. Ghizzone

Fact checked byMindy Valcarcel, MS

In this video, Ravi Salgia, MD, PhD, discussed findings from two studies presented at ASCO Annual Meeting — one investigating immunotherapy and the other targeted therapy — for the treatment of lung cancer.

“What we also find is not only immunotherapy was important in presentations, targeted therapy was incredibly important,” Salgia, medical oncologist, professor and Arthur & Rosalie Kaplan Chair of the medical oncology and therapeutics research department at City of Hope, said.

References:

Reckamp KL, et al. Overall survival from a phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non–small cell lung cancer previously treated with immunotherapy: Lung-MAP nonmatched substudy S1800A. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.
Sabari JK, et al. Activity of adagrasib (MRTX849) in patients with KRASG12C-mutated NSCLC and active, untreated CNS metastases in the KRYSTAL-1 trial. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interviews

Disclosures: Salgia reports no relevant financial disclosures.